Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is a troubling side effect of cancer treatment and is often poorly controlled. As a consequence, CINV is associated with substantially increased costs of care and significant interference with patients' lives. Inadequate control over CINV results from factors that include failure to provide guideline-adherent prophylactic medication and limitations in available therapies. Newer serotonin receptor antagonists, such as palonosetron, and addition of neurokinin-1 (NK-1) receptor antagonists to treatment have significantly decreased both acute and delayed CINV. A fixed-dose combination of palonosetron and a new NK-1 receptor, netupitant, is significantly superior to palonosetron alone and has small, but consistent, numerical advantages over aprepitant plus palonosetron for prevention of CINV. The combination of a serotonin receptor antagonist plus an NK-1 receptor antagonist has been shown to be cost-effective for prevention of CINV and the availability of a fixed-dose combination of netupitant and palonosetron may enhance this benefit.

Original languageEnglish (US)
Pages (from-to)825-834
Number of pages10
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume14
Issue number6
DOIs
StatePublished - Dec 1 2014

Fingerprint

Nausea
Vomiting
Drug Therapy
Neurokinin-1 Receptor Antagonists
Serotonin Antagonists
aprepitant
Therapeutics
Neurokinin-1 Receptors
Costs and Cost Analysis
palonosetron
Guidelines
Neoplasms
netupitant

All Science Journal Classification (ASJC) codes

  • Health Policy
  • Pharmacology (medical)

Cite this

Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting. / Schwartzberg, Lee.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 14, No. 6, 01.12.2014, p. 825-834.

Research output: Contribution to journalReview article

@article{65c85c5eb99e4cae969230d45ac400ef,
title = "Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting",
abstract = "Chemotherapy-induced nausea and vomiting (CINV) is a troubling side effect of cancer treatment and is often poorly controlled. As a consequence, CINV is associated with substantially increased costs of care and significant interference with patients' lives. Inadequate control over CINV results from factors that include failure to provide guideline-adherent prophylactic medication and limitations in available therapies. Newer serotonin receptor antagonists, such as palonosetron, and addition of neurokinin-1 (NK-1) receptor antagonists to treatment have significantly decreased both acute and delayed CINV. A fixed-dose combination of palonosetron and a new NK-1 receptor, netupitant, is significantly superior to palonosetron alone and has small, but consistent, numerical advantages over aprepitant plus palonosetron for prevention of CINV. The combination of a serotonin receptor antagonist plus an NK-1 receptor antagonist has been shown to be cost-effective for prevention of CINV and the availability of a fixed-dose combination of netupitant and palonosetron may enhance this benefit.",
author = "Lee Schwartzberg",
year = "2014",
month = "12",
day = "1",
doi = "10.1586/14737167.2014.957683",
language = "English (US)",
volume = "14",
pages = "825--834",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting

AU - Schwartzberg, Lee

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Chemotherapy-induced nausea and vomiting (CINV) is a troubling side effect of cancer treatment and is often poorly controlled. As a consequence, CINV is associated with substantially increased costs of care and significant interference with patients' lives. Inadequate control over CINV results from factors that include failure to provide guideline-adherent prophylactic medication and limitations in available therapies. Newer serotonin receptor antagonists, such as palonosetron, and addition of neurokinin-1 (NK-1) receptor antagonists to treatment have significantly decreased both acute and delayed CINV. A fixed-dose combination of palonosetron and a new NK-1 receptor, netupitant, is significantly superior to palonosetron alone and has small, but consistent, numerical advantages over aprepitant plus palonosetron for prevention of CINV. The combination of a serotonin receptor antagonist plus an NK-1 receptor antagonist has been shown to be cost-effective for prevention of CINV and the availability of a fixed-dose combination of netupitant and palonosetron may enhance this benefit.

AB - Chemotherapy-induced nausea and vomiting (CINV) is a troubling side effect of cancer treatment and is often poorly controlled. As a consequence, CINV is associated with substantially increased costs of care and significant interference with patients' lives. Inadequate control over CINV results from factors that include failure to provide guideline-adherent prophylactic medication and limitations in available therapies. Newer serotonin receptor antagonists, such as palonosetron, and addition of neurokinin-1 (NK-1) receptor antagonists to treatment have significantly decreased both acute and delayed CINV. A fixed-dose combination of palonosetron and a new NK-1 receptor, netupitant, is significantly superior to palonosetron alone and has small, but consistent, numerical advantages over aprepitant plus palonosetron for prevention of CINV. The combination of a serotonin receptor antagonist plus an NK-1 receptor antagonist has been shown to be cost-effective for prevention of CINV and the availability of a fixed-dose combination of netupitant and palonosetron may enhance this benefit.

UR - http://www.scopus.com/inward/record.url?scp=84909946718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909946718&partnerID=8YFLogxK

U2 - 10.1586/14737167.2014.957683

DO - 10.1586/14737167.2014.957683

M3 - Review article

VL - 14

SP - 825

EP - 834

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 6

ER -